A multicenter clinical trial of the effect of raloxifene hydrochloride for the prevention of health care problems caused by bilateral oophorectomy due to endometrial cancer

INTERVENTION: Group I: alfacalcidol (1microgram/day) and calcium aspartate 1.2g/day Drug admimistration period is 24 months. Group II: alfacalcidol (1microgram/day) and Raloxifene (60mg/day) and calcium aspartate 1.2g/day Drug admimistration period is 24 months. CONDITION: endometrial cancer Osteoporosis PRIMARY OUTCOME: The percentage change of bone mineral density of lumber spine and femoral neck SECONDARY OUTCOME: Lipid profiles INCLUSION CRITERIA: The patients who were diagnosed with endometrial cancer and underwent a surgery including bilateral oophorectomy at the five institutions participating in this study between 2004 and 2011.